0.5201
0.79%
+0.0041
After Hours:
.5075
-0.0126
-2.42%
Brainstorm Cell Therapeutics, Inc. stock is currently priced at $0.5201, with a 24-hour trading volume of 767.91K.
It has seen a +0.79% increased in the last 24 hours and a -3.83% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.49 pivot point. If it approaches the $0.5548 resistance level, significant changes may occur.
Previous Close:
$0.516
Open:
$0.516
24h Volume:
767.91K
Market Cap:
$35.54M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-0.8815
EPS:
-0.59
Net Cash Flow:
$-21.84M
1W Performance:
+14.06%
1M Performance:
-3.83%
6M Performance:
+188.94%
1Y Performance:
-81.16%
Brainstorm Cell Therapeutics, Inc. Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics, Inc.
Sector
Industry
Phone
201 488 0460
Address
1325 Avenue of Americas, 28th Floor, New York, NY
Brainstorm Cell Therapeutics, Inc. Stock (BCLI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
Dec-19-16 | Reiterated | Maxim Group | Buy |
Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics, Inc. Stock (BCLI) Latest News
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Nasdaq
Nasdaq
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 5.5% in April - Defense World
Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Crosses Above Two Hundred Day Moving Average of $0.36 - Defense World
Defense World
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Defense World
Investigation announced for Investors in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) over potential ... - openPR
openPR
Cell Therapy Market size is set to grow by USD 31041.49 million from 2023-2027, limitations in traditional organ ... - The Malaysian Reserve
The Malaysian Reserve
Brainstorm Cell Therapeutics, Inc. Stock (BCLI) Financials Data
Brainstorm Cell Therapeutics, Inc. (BCLI) Net Income 2024
BCLI net income (TTM) was -$16.63 million for the quarter ending September 30, 2023, a +34.65% increase year-over-year.
Brainstorm Cell Therapeutics, Inc. (BCLI) Cash Flow 2024
BCLI recorded a free cash flow (TTM) of -$21.84 million for the quarter ending September 30, 2023, a -7.88% decrease year-over-year.
Brainstorm Cell Therapeutics, Inc. (BCLI) Earnings per Share 2024
BCLI earnings per share (TTM) was -$0.43 for the quarter ending September 30, 2023, a +38.57% growth year-over-year.
About Brainstorm Cell Therapeutics, Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Cap:
|
Volume (24h):